Safety and efficacy of exenatide once weekly injection versus metformin, dipeptidyl peptidase-4 inhibitor, or thiazolidinedione as monotherapy in drug-naive patients with type 2 diabetes.

Trial Profile

Safety and efficacy of exenatide once weekly injection versus metformin, dipeptidyl peptidase-4 inhibitor, or thiazolidinedione as monotherapy in drug-naive patients with type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Exenatide (Primary) ; Metformin; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DURATION-4
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Dec 2011 Results published in Diabetes Care.
    • 08 Dec 2011 Results presented at the 21st World Diabetes Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top